12 Month Price Forecast For ADAG
Distance to ADAG Price Forecasts
ADAG Price Momentum
๐ค Considering Adagene (ADAG)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 7:24 PM UTC
ADAG Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, ADAG has a consensus that is neutral. The median price target is $8.00, with forecasts ranging from $3.50 to $19.06. Currently, there are 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
With ADAG currently trading at $1.86, the median price forecast suggests a 330.1% upside. The most optimistic forecast comes from at , projecting a 924.7% upside, while at provides the most conservative target, suggesting a 88.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADAG Analyst Consensus
ADAG Price Target Range
Latest ADAG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADAG.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 27, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $8.00 |
Sep 18, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Jul 22, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Jun 28, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Oct 4, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Sep 1, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Apr 21, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Mar 29, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Mar 21, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $5.00 |
Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $5.00 |
Dec 7, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $5.00 |
Sep 9, 2022 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $7.00 |
Feb 1, 2022 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $15.00 |
Jan 6, 2022 | Morgan Stanley | Overweight | Maintains | $27.00 | |
Jul 16, 2021 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $33.00 |
Jun 25, 2021 | China Renaissance | Buy | Initiates | $0.00 | |
Mar 8, 2021 | Jefferies | Buy | Initiates | $0.00 | |
Mar 8, 2021 | Morgan Stanley | Overweight | Initiates | $0.00 |
Stocks Similar to Adagene Inc.
The following stocks are similar to Adagene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adagene Inc. (ADAG) Financial Data
Adagene Inc. has a market capitalization of $82.34M with a P/E ratio of 0.0x. The company generates $815,746 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -4,534.8% and return on equity of -45.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Adagene Inc. (ADAG) Company Overview
About Adagene Inc.
Develops monoclonal antibody drugs for cancer.
The company focuses on researching, developing, and producing monoclonal antibody therapies targeting various types of cancers. It generates revenue primarily through the advancement of its product candidates through clinical trials, with potential future earnings from product sales upon successful commercialization.
Adagene's pipeline includes several clinical-stage candidates in various phases of testing, showcasing a robust commitment to innovative cancer treatments. The company was established in 2011 and operates from Suzhou, China, positioning itself within the rapidly growing biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
174
CEO
Dr. Peter P. Luo Ph.D.
Country
China
IPO Year
2021
Website
www.adagene.comAdagene Inc. (ADAG) Latest News & Analysis
A new report titled "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" is now available from ResearchAndMarkets.com, focusing on market opportunities in this sector.
The report signals growth potential in the CD47 inhibitor market, attracting investor interest in biotech sectors focused on innovative cancer therapies.
Adagene Inc. will present updated clinical data on its ADG126 therapy for microsatellite stable colorectal cancer at the ASCO GI Cancers Symposium on January 25, 2025.
Adagene's upcoming presentation on ADG126 could impact its stock price and investor sentiment, particularly if data shows promise for treating MSS CRC.
Adagene Inc. (ADAG) and Editas Medicine (EDIT) are being compared to sector performance for the year. Specific performance metrics were not provided in the excerpt.
Performance comparisons highlight relative strength or weakness, influencing investment decisions and sentiment toward Adagene and Editas in the biotech sector.
Adagene Inc. (ADAG) and ANI Pharmaceuticals (ANIP) performance compared to their sector has been reported, highlighting their relative standings in 2023.
Performance comparisons highlight relative strength or weakness, influencing investment decisions. Stronger performance may attract investors, while weaker results could raise concerns.
ADG126 shows enhanced safety and efficacy compared to ipilimumab, utilizing precision masking, novel ADCC mechanisms, and partial CTLA-4 blockade.
ADG126's enhanced safety and efficacy over ipilimumab could lead to increased market share and revenue for its developer, potentially influencing stock performance in the biotech sector.
Adagene Inc. (Nasdaq: ADAG) will present posters at the SITC 39th Annual Meeting in Houston from Nov. 6-10, 2024, focusing on novel antibody-based therapies.
Adagene's poster presentations at a major oncology conference could highlight advancements in its therapies, potentially boosting investor confidence and impacting stock performance.
Frequently Asked Questions About ADAG Stock
What is Adagene Inc.'s (ADAG) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Adagene Inc. (ADAG) has a median price target of $8.00. The highest price target is $19.06 and the lowest is $3.50.
Is ADAG stock a good investment in 2025?
According to current analyst ratings, ADAG has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ADAG stock?
Wall Street analysts predict ADAG stock could reach $8.00 in the next 12 months. This represents a 330.1% increase from the current price of $1.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adagene Inc.'s business model?
The company focuses on researching, developing, and producing monoclonal antibody therapies targeting various types of cancers. It generates revenue primarily through the advancement of its product candidates through clinical trials, with potential future earnings from product sales upon successful commercialization.
What is the highest forecasted price for ADAG Adagene Inc.?
The highest price target for ADAG is $19.06 from at , which represents a 924.7% increase from the current price of $1.86.
What is the lowest forecasted price for ADAG Adagene Inc.?
The lowest price target for ADAG is $3.50 from at , which represents a 88.2% increase from the current price of $1.86.
What is the overall ADAG consensus from analysts for Adagene Inc.?
The overall analyst consensus for ADAG is neutral. Out of 4 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are ADAG stock price projections?
Stock price projections, including those for Adagene Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.